You are here

  • Home
  • Archive
  • Volume 12, Issue 2
  • Continuous glucose monitoring improved glycaemic control in pregnant women with diabetes and reduced infant macrosomiaCommentary

Article Text

Article menu
Download PDFPDF
Treatment
Continuous glucose monitoring improved glycaemic control in pregnant women with diabetes and reduced infant macrosomia

https://doi.org/10.1136/ebn.12.2.43

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    H R Murphy

    Dr H R Murphy, University of Cambridge, Cambridge, UK; hm386@medschl.cam.ac.uk

    QUESTION

    Does continuous glucose monitoring (CGM) improve glycaemic control in pregnant women with diabetes and reduce infant macrosomia?

    METHODS

    Design:

    randomised controlled trial. Current Controlled Trials ISRCTN84461581.

    Allocation:

    concealed.

    Blinding:

    unblinded.

    Follow-up period:

    to delivery.

    Setting:

    2 diabetes antenatal clinics in the UK.

    Patients:

    71 pregnant women (mean age 31 y, mean gestational age 9 wks) who had type 1 diabetes (65% of women) or type 2 diabetes (35%) treated with insulin.

    Intervention:

    CGM plus standard antenatal care (n = 38) or standard care alone (n = 33). CGM was done every 4–6 weeks until 32 weeks of gestation. A subcutaneous sensor, attached to a portable monitor, was implanted by a nurse into the woman’s hip and worn for 5–7 days. The device recorded average tissue glucose concentrations every 5 minutes, but results …

    View Full Text

    Footnotes

    • Source of funding: Ipswich Diabetes Centre Charity Research Fund; study equipment donated by Medtronic UK.